- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eprazinone
Allopathy
Prescription Required
DCGI (Drugs Controller General of India)
Schedule H
Eprazinone belongs to the pharmacological class of Phosphodiesterase-4 inhibitors. Eprazinone appears to have Mucolytic and Bronchospasm.
Eprazinone was being studied for the treatment as well as relieving the symptoms and maintenance of episodes of chronic respiratory failure, cough, expectorant in chronic/acute bronchitis, rhinitis, flu, bronchial asthma, or chronic/acute cough.
The common side effects associated with Eprazinone are nausea, gastrointestinal problems, and diarrhea.
Eprazinone belongs to the pharmacological class of Phosphodiesterase-4 inhibitors. Eprazinone appears to have Mucolytic and Bronchospasm.
The drug Eprazinone is found to be attracted to the Mucin receptors inside the respiratory tract, hence preventing inflammatory proteins from attaching as well as reducing bronchospasm.
Eprazinone was being studied for the treatment as well as relieving the symptoms and maintenance of episodes of chronic respiratory failure, cough, expectorant in chronic/acute bronchitis, rhinitis, flu, bronchial asthma, or chronic/acute cough.
Eprazinone is found to be used only in European countries.
Eprazinone can be used in the treatment of:
- Rhinitis
- Cough
- Expectorant in chronic/acute bronchitis
- Chronic respiratory failure
- Flu
- Bronchial asthma
- Chronic / acute cough
Eprazinone can help to relieve symptoms and also for the treatment and maintenance of chronic respiratory failure, cough, expectorant in chronic / acute bronchitis, rhinitis, flu, bronchial asthma or chronic / acute cough.
Eprazinone was being studied in the following clinical indications:
- Rhinitis
- Cough
- Expectorant in chronic/acute bronchitis
- Chronic respiratory failure
- Flu
- Bronchial asthma
- Chronic / acute cough
Oral Tablets to be swallowed as a whole with water.
Oral Tablets:50mg
Orals Tablets
Maintaining health and cessation of smoking are a must.
Caffeine should be limited to use or avoided as it may lead to the risk of nervousness, rapid heartbeat, nausea, palpitations, etc.
Patients with an underlying liver disorder or liver dysfunction must avoid drinking alcohol.
A diet containing food with high sugar content and carbohydrates should be restricted. This includes pies, cakes, honey, cookies, jams, candies, chips, and bread. It is also advised to reduce or limit the intake of cholesterol and saturated fat and instead choose poultry, lean meat, or fish.
The dietary restrictions need to be individualized as per the patient's requirements.
Eprazinone might be contraindicated under the following conditions:
- Hypersensitivity to the ingredients of the medication
No formal drug interaction studies had been conducted.
- Nausea
- Gastrointestinal troubles
- Diarrhea
- Spitzer W (June 1980). "[The efficacy of eprazinone dihydrochloride (Eftapan) in double-blind studies]". Fortschritte der Medizin. 98 (22): (871-4).
- https://go.drugbank.com/drugs/DB08990
- https://www.vinmec.com/en/news/health-news/general-health-check/eprazineone-uses-dosage-and-side-effects-note/#:~:text=Eprazinone side effects,experience while taking the medicine.
- https://echa.europa.eu/substance-information/-/substanceinfo/100.030.782
- https://www.ebi.ac.uk/chebi/searchId.do?chebiId=82716
- https://pharmaoffer.com/api-excipient-supplier/eprazinone
- https://www.selleckchem.com/products/eprazinone-2hcl.html
- https://drugcentral.org/drugcard/1035